Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do
Executive Summary
Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.
You may also be interested in...
Roche/GSK Boniva Launch Will Await Less Frequent Dose Approval
Roche and GlaxoSmithKline will hold off launching the osteoporosis agent Boniva (ibandronate) until approval of a less frequent dosing regimen
Roche/GSK Boniva Launch Will Await Less Frequent Dose Approval
Roche and GlaxoSmithKline will hold off launching the osteoporosis agent Boniva (ibandronate) until approval of a less frequent dosing regimen
Roche Pares Back To Specialty Care: U.S. Sales Force Will Be Cut By 24%
Roche will concentrate on specialty care products in the U.S. as part of the restructuring of its global pharmaceutical division.